How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?  

Should these patients have a different threshold for utilizing a CDK4/6 inhibitor in the front line metastatic or as part of adjuvant therapy, or SERDs where eligible?



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at NYU Winthrop Hospital
Great review
Medical Oncologist at NorthEast Onc Assocs
Great summary and guidance in this patient populat...
Sign in or Register to read more